Stories from Munich

Language:
english
Content:
All
Date:
All
Yesterday
Last 7 days
April
Reset
29.08.2017 – 14:01

Daiichi Sankyo Europe GmbH

New Sub-analysis Data Highlights the Benefit of LIXIANA® (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring

Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...
19.07.2017 – 15:33

BMW Group

BMW Motorrad sets a new sales record in the first half of the year for the fifth time in succession / Sales increase by 9.5% to 88,389 vehicles in the first half of 2017

Munich (ots) - The aim is to achieve a new all-time sales record for the year as a whole BMW Motorrad sold more motorcycles and maxi scooters in 2017 than ever before. Compared to the previous year, deliveries increased by 9.5%. As of June 2017 a total of 88,389 vehicles (previous year: 80,754 units) were supplied ...
17.07.2017 – 09:58

Consline AG

Social Media Monitoring: Automated Relevance Recognition with Artificial Intelligence / Breakthrough in the reliable identification of relevant social media posts

Munich (ots) - Based on its constantly developed technology and specific methodology, German company Consline AG has made a breakthrough in automated recognition of relevant posts. The basis are Deep Learning techniques of Artificial Intelligence (Naive Bayes, SVM, SGD), which, like the human mind, can improve their ...
17.07.2017 – 09:02

Daiichi Sankyo Europe GmbH

CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

Munich (ots/PRNewswire) - - Recommended label update for LIXIANA® provides guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion - Update is based on data from ENSURE-AF, the largest prospective randomised clinical trial of anticoagulation for ...
27.04.2017 – 15:02

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Munich (ots/PRNewswire) - - ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) ...
30.03.2017 – 14:00

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

Munich (ots/PRNewswire) - - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled ...
08.12.2016 – 13:01

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA® (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Munich (ots/PRNewswire) - First patient enrolled in EMIT-AF/VTE study (NCT02950168), a European registry to assess edoxaban management in patients undergoing medical procedures[1] Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the first patient has been enrolled in the EMIT-AF/VTE ...
13.10.2016 – 09:02

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA® (edoxaban)

Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
30.09.2016 – 11:03

Daiichi Sankyo Europe GmbH

New Analysis Shows Maintained Efficacy and Safety of LIXIANA® (edoxaban) in Patients with Acute VTE Requiring a Reduced Dose Based on Clinical Criteria

Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...